Quarterly ResultAug 13, 2026, 04:15 PM
Acurx Pharma Q2 Net Loss $(2.25M); Going Concern Doubt Raised
AI Summary
Acurx Pharmaceuticals reported a net loss of $(2.25) million for the three months ended June 30, 2026, and $(3.94) million for the six months ended June 30, 2026. Despite raising $6.22 million through financing activities in the first half of 2026, the company's management has raised substantial doubt about its ability to continue as a going concern, citing insufficient cash to meet anticipated requirements for the next 12 months. The company continues to incur significant R&D expenses for its antibiotic candidates.
Key Highlights
- Substantial doubt raised about Acurx Pharmaceuticals' ability to continue as a going concern.
- Net loss for Q2 2026 was $(2.25) million, compared to $(2.25) million in Q2 2025.
- Net loss for H1 2026 was $(3.94) million, an improvement from $(4.40) million in H1 2025.
- Cash balance increased to $10.66 million as of June 30, 2026, from $7.56 million at year-end 2025.
- Raised $6.22 million from financing activities in the first six months of 2026.
- Research and development expenses increased to $1.07 million in Q2 2026 from $0.52 million in Q2 2025.
- Basic and diluted net loss per share improved to $(0.53) in Q2 2026 from $(1.89) in Q2 2025.
Price Impact
More from ACXP